INAB · In8bio, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| R&D | $10.21M | $16.96M | $16.83M | $14.06M | $5.38M |
| SG&A | $9.65M | $12.64M | $13.51M | $14.46M | $3.18M |
| Total Operating Expenses | $19.86M | $30.67M | $30.34M | $28.52M | $8.56M |
| D&A | $1.00M | $976.0K | $962.0K | $147.0K | $88.0K |
| Operating Income | ($19.44M) | ($30.44M) | ($30.34M) | ($28.52M) | ($8.56M) |
| Interest Expense | - | - | - | - | - |
| Income Tax | $0 | $0 | $0 | $0 | $0 |
| Net Income | ($19.44M) | ($30.44M) | ($30.01M) | ($28.52M) | ($8.56M) |
| EPS - Basic | ($4.44) | ($17.10) | ($30.00) | ($44.10) | - |
| EPS - Diluted | ($4.44) | ($17.10) | ($30.00) | ($44.10) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | $27.31M | $11.39M | $21.54M | $18.43M | $37.27M |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | $309.0K | $389.0K | $924.0K | $2.09M | $395.0K |
| Current Assets | $27.88M | $12.58M | $24.63M | $22.23M | $38.98M |
| Total Assets | $32.28M | $20.94M | $33.71M | $33.04M | $42.22M |
| Current Liabilities | $3.16M | $3.08M | $5.39M | $5.82M | $2.26M |
| Long-term Debt | - | - | - | - | - |
| Total Liabilities | $4.72M | $6.47M | $8.77M | $10.31M | $4.04M |
| Stockholders' Equity | $27.56M | $14.48M | $24.94M | $22.73M | $38.18M |
| Retained Earnings | ($141.10M) | ($121.66M) | ($91.22M) | ($61.21M) | ($32.69M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | ($12.71M) | ($24.15M) | ($23.34M) | ($24.12M) | ($7.13M) |
| Investing Cash Flow | $0 | ($187.0K) | ($600.0K) | ($3.71M) | $0 |
| Financing Cash Flow | $28.64M | $14.18M | $27.04M | $8.99M | $24.52M |
| CapEx | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | - | - | - | - | - |
| Operating margin | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - |
| Return on assets | -60.2% | -145.3% | -89.0% | -86.3% | -20.3% |
| Return on equity | -70.5% | -210.2% | -120.3% | -125.5% | -22.4% |
| Return on invested capital | - | - | - | - | - |
| Liquidity | |||||
| Current ratio | 8.82 | 4.08 | 4.57 | 3.82 | 17.28 |
| Quick ratio | 8.82 | 4.08 | 4.57 | 3.82 | 17.28 |
| Cash ratio | 8.64 | 3.69 | 3.99 | 3.17 | 16.52 |
| Leverage | |||||
| Debt / Equity | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - |
| Interest coverage | - | - | - | - | - |
| Equity multiplier | 1.17 | 1.45 | 1.35 | 1.45 | 1.11 |
| Liabilities / Assets | 0.15 | 0.31 | 0.26 | 0.31 | 0.10 |
| Efficiency | |||||
| Asset turnover | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - |
| Valuation | |||||
| P / E | - | - | - | - | - |
| P / B | 0.4x | 28.5x | 49.6x | - | - |
| P / S | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - |
| Growth | |||||
| Revenue growth (YoY) | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - |
| Operating income growth (YoY) | 36.1% | -0.3% | -6.4% | -233.3% | - |
| Net income growth (YoY) | 36.1% | -1.4% | -5.2% | -233.3% | - |
| EPS growth (YoY) | 74.0% | 43.0% | 32.0% | - | - |
| EPS CAGR (3y) | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | 90.3% | -41.9% | 9.7% | -40.5% | - |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
4/9
Neutral
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✓No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing IN8BIO against the 5 most active filers in the same SIC group.